Nausea and Vomiting

Encyclopedia of Neuroscience

Volumn , Issue , 2009, Pages 29-35

  Andrews, P L R ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882263041     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-008045046-9.00657-4     Document Type: Chapter

References (30)

1. Andrews P.L.R. Postoperative nausea and vomiting. Problems of the Gastrointestinal Tract in Anesthesia 1999, 267-288. Springer, Berlin. M.K. Herbert, P. Holzer, N. Rower (Eds.).
2. Crampton G.H. Motion and Space Sickness 1990, CRC Press, Boca Raton, FL.
3. Diemunsch P., Grelot L. Potential of substance P antagonists as antiemetics. Drugs 2000, 60:533-546.
4. Ernst E., Pittler M.H. Efficacy of ginger for nausea and vomiting: A systematic review of randomised clinical trials. British Journal of Anaesthesiology 2000, 84:367-371.
5. Fink-Jensen A., Judge M.E., Hansen J.B., et al. Inhibition of cisplatin-induced emesis in ferrets by the non-NMDA receptor antagonists NBQX and CNQX. Neuroscience Letters 1992, 137:173-177.
6. Flaxman S.M., Sherman P.W. Morning sickness: A mechanism for protecting mother and embryo. Quarterly Review of Biology 2000, 75:113-148.
7. Girod V., Dapzol J., Bouvier M., Grelot L. The COX inhibitors indomethacin and meloxicam exhibit anti-emetic activity against cisplatin-induced emesis in piglets. Neuropharmacology 2002, 42:428-436.
8. Hesketh P.J., Gralla R.J., Webb R.T., et al. Randomised phase II study of the neurokinin-1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. Journal of Clinical Oncology 1999, 17:338-343.
9. Koch K.L. Approach to the patient with nausea and vomiting. Textbook of Gastroenterology 1995, vol. 1:731-749. Lippincott, Philadelphia. 2nd edn. T. Yamada (Ed.).
10. Kris M.G., Radford J., Pizzo B.A., et al. Control of emesis following cisplatin by CP-122,721, a selective NK1 receptor antagonist. Journal of the National Cancer Institute 1997, 89:817-818.
11. Lehmann A., Karrberg L. Effects of N-Methyl- D-aspartate receptor antagonists on cisplatin-induced emesis in the ferret. Neuropharmacology 1996, 35:475-481.
12. Lien H.-C., Sun W.M., Chen Y.-H., Kim H., et al. Effects of ginger on motion sickness and gastric slow-wave dysrhythmias induced by circular vection. American Journal of Physiology and Gastrointestinal Liver Physiology 2003, 284:G481-G489.
13. Lucot J.B. Effects of N-methyl- D-aspartate antagonists on different measures of motion sickness in cats. Brain Research Bulletin 1998, 47:407-411.
14. Mayer D.J. Acupuncture: An evidence-based review of the clinical literature. Annual Review of Medicine 2000, 51:49-63.
15. Miller A.D., Grelot L. The neural basis of nausea and vomiting. Vestibular Autonomic Regulation 1996, 85-94. CRC Press, Boca Raton, FL. B.J. Yates, A.D. Miller (Eds.).
16. Morrow G.R., Roscoe J.A., Hickock J.T., Andrews P.L.R., et al. Nausea and emesis: Evidence for a biobehavioural perspective. Support Care Cancer 2002, 10:96-105.
17. Navari R.M., Reinhardt R.R., Gralla R.J., et al. Reduction of cisplatin-induced emesis by a selective neurokinin receptor antagonist. New England Journal of Medicine 1999, 340:190-195.
18. Quigley E.M.M., Hasler W.L., Parkman H.P. AGA Technical review on nausea and vomiting. Gastroenterology 2001, 120:263-286.
19. Serotonin and the Scientific Basis of Anti-emetic Therapy 1995, Oxford Clinical Communications, Oxford. D.J.M. Reynolds, P.L.R. Andrews, C.J. Davis (Eds.).
20. Roscoe J.A., Hickok J.T., Morrow G.R. Patient expectations as predictor of chemotherapy-induced nausea. Annals of Behavioral Medicine 2000, 22:121-126.
21. Rudd J.A., Cheng C.H.K., Naylor R.J. Modulation of emesis by fentanyl and opioid receptor antagonists in Suncus murinus (house musk shrew). European Journal of Pharmacology 1999, 374:77-84.
22. Sanger G.J., Andrews P.L.R. Emesis. Drug Therapy for Gastrointestinal and Liver Diseases 2001, 45-61. Martin Dunitz Ltd, London. M.J.G. Farthing, A.B. Ballinger (Eds.).
23. Simoneau M.S., Hamza, Mata H.P., et al. The cannabinoid agonist WIN55, 212-2 suppresses opioid-induced emesis in ferrets. Anesthesthesiology 2001, 94:882-887.
24. The Handbook of Nausea and Vomiting 1993, CRC Press-Parthenon Publishing, New York. M.H. Sleisenger (Ed.).
25. Tramer M.R., Moore R.A., Reynolds D.J.M., McQuay H.J. A quantitative systematic review of ondansetron in treatment of established postoperative nausea and vomiting. British Medical Journal 1997, 314:1088-1092.
26. Tramer M.R., Carroll D., Campbell F.A., et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systemic review. British Medical Journal 2001, 323:1-8.
27. Treisman M. Motion sickness: An evolutionary hypothesis. Science 1977, 197:493-495.
28. Van Belle S., Lichinitser M.R., Navari R.M., et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer 2002, 94:3032-3041.
29. Van Sickle M.D., Oland L.D., Ho W., et al. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 2001, 121:767-774.
30. Yates B.J., Miller A.D., Lucot J.B. Physiological basis and pharmacology of motion sickness: An update. Brain Research Bulletin 1998, 47:395-406.